GW Pharmaceuticals PLC- (NASDAQ:GWPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Monday. The firm presently has a $119.00 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s price objective would suggest a potential upside of 11.93% from the stock’s current price.

According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “

GWPH has been the subject of a number of other research reports. ValuEngine raised shares of GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. BidaskClub raised shares of GW Pharmaceuticals PLC- from a “strong sell” rating to a “sell” rating in a research note on Wednesday, June 14th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $208.00 price objective on shares of GW Pharmaceuticals PLC- in a research note on Tuesday, May 9th. Maxim Group reaffirmed a “buy” rating and issued a $135.00 price objective on shares of GW Pharmaceuticals PLC- in a research note on Thursday, May 25th. Finally, TheStreet cut shares of GW Pharmaceuticals PLC- from a “c-” rating to a “d+” rating in a research note on Wednesday, May 10th. Three investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $156.05.

GW Pharmaceuticals PLC- (GWPH) traded up 0.17% during trading on Monday, hitting $106.33. 209,752 shares of the stock traded hands. The company has a 50-day moving average price of $101.55 and a 200-day moving average price of $115.09. The stock’s market cap is $2.69 billion. GW Pharmaceuticals PLC- has a 12 month low of $79.62 and a 12 month high of $137.88.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.50) by $0.20. GW Pharmaceuticals PLC- had a negative net margin of 2,112.29% and a negative return on equity of 37.28%. The business had revenue of $2.04 million during the quarter, compared to analysts’ expectations of $2.07 million. During the same period last year, the company posted ($0.06) EPS. GW Pharmaceuticals PLC-‘s revenue for the quarter was down 23.0% on a year-over-year basis. Equities research analysts expect that GW Pharmaceuticals PLC- will post ($5.34) EPS for the current year.

TRADEMARK VIOLATION WARNING: This story was published by Daily Political and is owned by of Daily Political. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/07/17/gw-pharmaceuticals-plc-gwph-upgraded-to-buy-at-zacks-investment-research.html.

A number of hedge funds and other institutional investors have recently modified their holdings of GWPH. ING Groep NV raised its position in shares of GW Pharmaceuticals PLC- by 89.5% in the first quarter. ING Groep NV now owns 19,222 shares of the biopharmaceutical company’s stock valued at $2,325,000 after buying an additional 9,078 shares during the period. C WorldWide Group Holding A S raised its position in shares of GW Pharmaceuticals PLC- by 10.6% in the first quarter. C WorldWide Group Holding A S now owns 23,026 shares of the biopharmaceutical company’s stock valued at $2,785,000 after buying an additional 2,202 shares during the period. Jennison Associates LLC raised its position in shares of GW Pharmaceuticals PLC- by 212.1% in the first quarter. Jennison Associates LLC now owns 466,345 shares of the biopharmaceutical company’s stock valued at $56,400,000 after buying an additional 316,926 shares during the period. Wells Fargo & Company MN raised its position in shares of GW Pharmaceuticals PLC- by 10.2% in the first quarter. Wells Fargo & Company MN now owns 11,462 shares of the biopharmaceutical company’s stock valued at $1,386,000 after buying an additional 1,063 shares during the period. Finally, Greenleaf Trust raised its position in shares of GW Pharmaceuticals PLC- by 10.1% in the first quarter. Greenleaf Trust now owns 82,194 shares of the biopharmaceutical company’s stock valued at $9,941,000 after buying an additional 7,508 shares during the period. Institutional investors and hedge funds own 75.63% of the company’s stock.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC- (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.